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Background: Despite evident success of malaria control in many sites in the Arabian Peninsula, malaria remains
endemic in a few spots, in Yemen and south-west of Saudi Arabia. In addition to local transmission, imported
malaria sustains an extra source of parasites that can challenge the strengths of local control strategies. This study
examined the genetic diversity of Plasmodium falciparum in Yemen and mutations of drug resistant genes, to
elucidate parasite structure and distribution of drug resistance genotypes in the region.
Methods: Five polymorphic loci (MSP-2, Pfg377 and three microsatellites on chromosome 8) not involved in anti-
malarial drug resistance, and four drug resistant genes (pfcrt, pfmdr1, dhfr and dhps) were genotyped in 108 P.
falciparum isolates collected in three sites in Yemen: Dhamar, Hodeidah and Taiz.
Results: High diversity was seen in non-drug genes, pfg377 (He = 0.66), msp-2 (He = 0.80) and three microsatellites
on chr 8, 7.7 kb (He = 0.88), 4.3 kb (He = 0.77) and 0.8 kb (He = 0.71). There was a high level of mixed-genotype
infections (57%), with an average 1.8 genotypes per patient. No linkage disequilibrium was seen between drug
resistant genes and the non-drug markers (p < 0.05). Genetic differentiation between populations was low (most
pair-wise FST values <0.03), indicating extensive gene flow between the parasites in the three sites.
There was a high prevalence of mutations in pfmdr1, pfcrt and dhfr; with four mutant pfmdr1 genotypes (NFCDD
[57%], NFSND[21%], YFCDD[13%] and YFSND[8% ]), two mutant pfcrt genotypes (CVIET[89%] and SVMNT[4%]) and
one mutant dhfr genotype (ICNI[53.7%]). However, no dhps mutations were detected.
Conclusion: The high diversity of P. falciparum in Yemen is indicative of a large parasite reservoir, which represents
a challenge to control efforts. The presence of two distinct pfcrt genotype, CVIET and SVMNT, suggests that
chloroquine resistance can possibly be related to a migratory path from Africa and Asia. The absence of the triple
mutant dhfr genotype (IRN) and dhps mutations supports the use of artesunate + sulphadoxine-pyrimethamine as
first-line therapy. However, the prevalent pfmdr1 genotype NFSND [21%] has previously been associated with
tolerance/resistance response to artemisinin combination therapy (ACT). Regular surveys are, therefore, important to
monitor spread of pfmdr1 and dhfr mutations and response to ACT.
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The Arabian Peninsula lies at the fringes of malaria
endemicity where successful control measures have
brought local transmission to halt in many countries in the
region, e.g. Bahrain, Kuwait and United Arab Emirates
(UAE) [1]. However, some sites in Yemen and southern
Saudi Arabia remain malarious, with a high prevalence of
drug-resistant Plasmodium falciparum parasites [2,3]. In
addition, imported malaria cases, via asymptomatic travel-
lers from malaria-endemic areas, sustain a major challenge
for possible rebound of local transmission [4].
The region attracts numerous migrations from Africa
and Asia. Over the past two decades political instability
has resulted in mass movement of people from the
Horne of Africa (Somalia, Eritrea and Ethiopia) into
Yemen and Saudi Arabia [5]. These countries are known
for high prevalence of drug-resistant P. falciparum mal-
aria. In addition, the region attracts a lot of skilled
workers from Asia. However, the impact of these migra-
tions on the gene pool of local malaria parasites in the
Arabian Peninsula remains unclear as information on
malaria parasites genetics is scarce.
In Yemen, over 60% of the population live in areas
with stable malaria transmission [6]. Plasmodium falcip-
arum is responsible for about 90% of malaria cases. Indi-
genous chloroquine resistance (CQR) was reported in
1989 [7,8], and since then it spread to different regions
in the highland and lowland areas in Taiz [7] and
Hodeidah [9]. Cross- sectional surveys in 2008 and 2009
in Taiz, Hodeidah, Dhamar and Rymah showed high
prevalence of the CQR marker pfcrt 76 T [2]. However,
resistance to sulphadoxine-pyrimethamine (SP) is rare in
Yemen [2,10]. Currently SP is used in combination with
artesunate (AS) as first-line treatment of uncomplicated
falciparum malaria. In addition, artemether-lumefantrine
(AL) is used as a second-line therapy for treatment
failure [11].Figure 1 Geographical location of the three studied sites in Yemen: HThe present study examined genetic diversity of P.
falciparum in Yemen, and distribution of genes impli-
cated in resistance to widely used anti-malarial drugs, in-
cluding, chloroquine, SP, mefloquine and artemisinin.
Such analysis will provide desirable information on the
genetics structure of P. falciparum in the Arabian
Peninsula, and the prospect of evolution of drug resist-
ance following recent shift of malaria therapy to artemi-
sinin combination therapy (ACT).Methods
Study sites and sampling
One hundred and fifteen finger-prick blood samples
were collected, from microscopy-confirmed malaria
cases, in three localities in Yemen (Dhamar, Hodeidah
and Taiz) (Figure 1) Dhamar (Latitude: 14°32′33″ N,
Longitude: 44°24′18″ E ) is a highland (2407 m above sea)
where transmission occurs throughout the year. Hodeidah
(Latitude: 14°48′08″N, Longitude: 42°57′04″E) is a coastal
area where malaria transmission occurs in winter and Taiz
(Latitude: 13°34′44″N, Longitude: 44°01′19″E) is a
mountainous area (1311 m above sea) and transmission
occurs in summer [2]. Ethical clearance was obtained
from Faculty of Medicine, Sana’a University, Yemen. In-
formed consent was obtained from each participant before
enrolment in the study.Non drug-resistance genes
pfg377 and msp-2
The pfg377 gene primers amplify a polymorphic region,
encoding a seven degenerate amino acid repeats; alleles
of this gene, vary by multiples of 21 base pairs [12].
Polymerase chain reaction (PCR) primers and conditions
for amplification were as described previously [12], with
minor modification where the nested primer 377R3D1
was labelled.odeidah (1), Dhamar (2), and Taiz (3).
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3D7, which differ in the sequence of the dimorphic
central region, block 3 [13]. PCR primers and conditions
for amplification of each type were described by Aubouy
et al. [14].
The fluorescent PCR products of pfg377 and msp-2
were analysed in an ABI 3130XL Genetic Analyzer, and
alleles were visualized and sized on Genesmapper v. 4
(Applied Biosystems).
Microsatellites
Three single copy microsatellites on chr 8 flanking the
dhps (0.8, 4.3 and 7.7 kb from the 3′ end of the gene)
were types. All isolates examined in this study harbour
the wild-type dhps, therefore, the above microsatellites
are not influenced by drug pressure and were used to
examine parasite diversity and population structure.
The microsatellites were examined as described by
Roper et al. [15]. Fluorescent PCR products were
analysed in an ABI 3130XL Genetic Analyzer, and alleles
were visualized and sized on Genemapper v.4 (Applied
Biosystems).
Drug resistance genes
pfcrt, pfmdr1, dhfr and dhps
Alleles of the pfcrt, pfmdr1, dhfr and dhps genes were
amplified using two rounds of PCR [1,16-19]. The ampli-
fied fragments of each gene encompasses mutations as-
sociated with CQR (pfcrt-72,-74,-75, and −76), and
multidrug resistant gene-1 (pfmdr1-86, -184, 1034,1042
and 1246), pyrimethamine resistance (dhfr-51, -59, -108,
and −164), sulphadoxine resistance (dhps-436, -437, -
540, and −613).
PCR fragments of the isolates, together with control
clones (3D7, Hb3 and Dd2) of known sequence and drug
response, were then sequenced. The parasites were
obtained from The European Malaria Reference Reagent
Repository. 3D7 and Dd2, are chloroquine sensitive and
resistant clones, with pfcrt76K and pfcrt76T codons, re-
spectively [20], and codons pfmdr1 86 N and 86Y associ-
ated with susceptible and resistance response to
choloroquine, respectively [21]. The 3D7 clone is known
to be pyrimethamine and sulphadoxine sensitive carrying
wild-type dhfr and dhps gene, implicated in resistance to
the two drug respectively [22], while Dd2 is a pyrimeth-
amine and sulphadoxine resistance, carrying mutations
in dhfr and dhps associated with in vitro resistance [23].
The PCR products were first purified using ExoSAP-IT
(USB) as described by the manufacturer. Sequencing was
carried out using BigDye Terminator v3.1 cycle (ABI,
UK) and run on a thermocycler. Initial sequences were
compared with reference sequences in the PlasmoDB
database of P. falciparum genomic using BLASTN,
BioEdit and Lasergene software.Statistical analysis
The prevalence of an allele and genotype were calculated
as percentage of all the alleles and genotypes detected at
a given locus among the examined isolates. The
expected heterozygosity index (He), which measures the
diversity at a locus examined, was calculated for non-
drug resistant genes using microsatellite Toolkit software
as described elsewhere [24].
The multiplicity of infection was defined as the pro-
portion of people who carry more than one allele (geno-
type) for any of the examined genes, and the minimum
number of clones per infection was estimated as the lar-
gest number of alleles at any of the examined loci [25].
Gamete linkage disequilibrium (LD) values between all
pairs of loci were calculated for all samples GENEPOP
v.4.1 [26]. For these analyses, only the predominant
alleles at each locus, indicating clonal infections, were
used.
To examine whether allele frequencies differ between
parasite populations in Dhamar, Hodeidah and Taiz, FST
indices were calculated using Weir and Cockerham's
method [27] estimator of Wright's F-statistics using the
computer package GENEPOP v.4.1 [26]. A permutation
test (n = 10,000) was applied (permuting alleles over
populations) to test whether FST indices were signifi-
cantly different from zero.
Principal coordinate analysis (PCoA) was carried out
to examine the genetic similarities (of alleles of non-
drug resistant genes) between P. falciparum isolates in
the three coding sites using Genalex Version 6.5 [28].
The two-dimensional PCoA plot shows the relationships
between the haplotypic variants found in the three
populations.
Results
Out of the 115 samples with microscopy-confirmed mal-
aria parasites, 108 proved to be P. falciparum and pro-
duced the expected PCR amplicons for the examined
genes (pfcrt, pfmdr1, dhfr, dhps, pfg377 and msp-2). The
other seven (6.4%) isolates were most likely to have been
Plasmodium vivax, which is found in Yemen.
Diversity and structure of non drug-resistant genes
The five non drug-resistant loci (pfg377, msp-2 and three
microsatellites on chr 8) were highly polymorphic,
with a number of alleles per locus ranging from five
(pfg377) to 45 (msp-2). Diversity, expressed as expected
hetrozygosity (He), was high for all loci, ranging from
0.51 to 0.89, with average of 0.66 (for pfg377) and 0.80
(for msp-2) (Table 1), reflecting high diversity among the
examined isolates.
No LD was seen between genes involved in drug re-
sistance (pfcrt, pfmdr1 and dhfr) and non-drug loci
(pfg377 and msp-2) (P < 0.001). However, loci involving
Table 1 Allelic diversity (heterozygosity, He) at five non
drug resistance loci among Plasmodium falciparum in
three sites in Yemen
Dhamar Hodeidah Taiz Fst
He He He
(n = 29) (n = 17) (n = 62)
Chr 8
7.7Kb 0.88 0.08 0.87 0.021
4.3Kb 0.77 0.8 0.84 0.020
0.8Kb 0.71 0.77 0.66 0.024
Chr 2
MSP-2 0.61 0.51 0.89 0.141
Chr 12
Pfg377 0.63 0.73 0.66 0.003
Mean 0.72 0.72 0.78
Al-Hamidhi et al. Malaria Journal 2013, 12:244 Page 4 of 8
http://www.malariajournal.com/content/12/1/244resistance to one drug (pfcrt and pfmdr1) had a greater
average LD than those not involved in drug resistance
loci (P < 0.01).
Alleles at non drug-resistance loci were distributed
widely across parasites in different sites in Yemen
(Table 1), and any ‘private’ alleles (detected in only one
population) existed at very low frequencies (Additional
file 1). Comparison of parasites in the three sites showed
low Fst values, ranged from 0.141 to 0.003, suggesting
frequent gene flow (Table 1). Furthermore, PCoA ana-
lysis showed no pattern of clustering of parasites in any
of the three geographical sites (Figure 2).
Multiplicity of Plasmodium falciparum infection
There was a high prevalence of mixed genotype infec-
tion, 57% of the isolates carried more than one genotype.Figure 2 Graphical plotting of the PCoA based on genetic variation o
microsatellites in chr 8) among Plasmodium falciparum parasites in th
Blue icon = Taiz, red icon = Dhamar and green icon = Hodeidah.The number of genotypes per infected person (the max-
imum number of alleles observed at any locus) was esti-
mated as 1.8, assuming that each clone is readily
transmissible to mosquito, this reflects a high rate of
cross-mating [25].
Distribution of drug resistance markers
pfcrt
Out of the 108 P. falciparum isolates successfully exam-
ined, four (4%), 96 (89%), 96 (89%) and 100 (93%)
harboured mutations at codons 72, 74, 75 and 76 re-
spectively (Table 2). Ninety-six (89%), four (4%) and
eight (7%) isolates carried the pfcrt genotypes CVIET,
SVMNT and the wild-type (CVMNK), respectively
(Table 2).
All isolates carrying the wild-type pfcrt genotype
(CVMNK) were detected in Taiz, except one seen in
Hodeidah. Similarly, isolates with the mutant pfcrt geno-
type SVMNT were only seen in Hodeidah.
pfmdr1
There was a, high prevalence of pfmdr1 mutation at
codon N86Y (20%), Y184F (99%), S1034C (70%) and
N1042D (70%), while no mutation was seen at codon
1246 (Table 2). The majority of isolates (57%) carried the
mutant genotype (NFCDD), while 21%, 13%, and 8%
of them harboured the mutant genotype (NFSND),
(YFCDD), and (YFSND) respectively. However, only one
isolate carried the wild-type (1%) (Table 2).
dhfr
No mutations were seen at codons 59 and 164. However,
58 (54%) isolates showed mutations at codons N51I and
S108N (Table 2). A large proportion of the isolatesf non drug-resistant genes (Pfg377, MSP-2 and three
ree sites in Yemen, and variation representation by each axis.
Table 2 Prevalence of mutant alleles of pfcrt, pfmdr1, dhfr
and dhps genes among 108 Plasmodium falciparum in
three sites in Yemen
All Taiz Dhamar Hodeidah
pfcrt n (%) n (%) n (%) n (%)
Alleles
72S 4 (4) 0 0 4 (4)
74I 96 (89) 55(50.9) 29(26.9) 12(11)
75E 96 (89) 55(50.9) 29(26.9) 12(11)
76T 100 (93) 55(50.9) 29(26.9) 16(14.8)
Genotypes
CVMNK 8 (7) 7(6.5) 0 1(1)
SVMNT 4 (4) 0 0 4 (4)
CVIET 96 (89) 55(50.9) 29(26.9) 12(11)
pfmdr1
Alleles
86Y 22 (20) 18(16.7) 3(3) 1(1)
184 F 107 (99) 62(57) 28(25.9) 17(15.7)
1034C 76 (70) 44(40.7) 20(18.5) 12(11)
1042D 76 (70) 44(40.7) 20(18.5) 12(11)
1246Y 0 0 0 0
Genotypes
NYSND 1 (1) 0 1(1) 0
NFSND 23 (21) 12(11) 6(5.6) 5(4.6)
YFSND 8 (8) 6(5.6) 2(2) 0
NFCDD 62 (57) 32(29.6) 19(17.6) 11(10)
YFCDD 14 (13) 12(11) 1(1) 1(1)
dhfr
Alleles
51I 58 (54) 40(37) 12(11) 6(5.6)
59R 0 0 0 0
108N 58 (54) 40(37) 12(11) 6(5.6)
164 L 0 0 0 0
Genotypes
NCSI 50 (46) 22(20.4) 17 11(10)
ICNI 58 (54) 40(37) 12(11) 6(5.6)
dhps
Alleles
436 F 0 0 0 0
437G 0 0 0 0
540E 0 0 0 0
613S 0 0 0 0
Genotypes
SAKA 108 (100) 62 (57) 29(26.9) 17(15.7)
n = number of isolates, mutated amino acids are bold and underlined.
Al-Hamidhi et al. Malaria Journal 2013, 12:244 Page 5 of 8
http://www.malariajournal.com/content/12/1/244(54%) carried the mutant genotype (ICNI), while 50
(46%) isolates harboured the wild-type (NCSI) (Table 2).
dhps
Unlike the other drug-resistant genes, no mutation was
detected at all codons 436, 437, 540 and 613, which are
implicated in sulphadoxine resistance.
Discussion
Many sites in the Arabian Peninsula turned into “mal-
aria-free” following intensive control efforts mounted
over a relatively short period of time [1]. In contrast, in
Yemen and southwest Saudi Arabia malaria remains re-
silient to control efforts. Some of the challenges facing
the prospect of elimination, in these sites, is the intro-
duction of drug resistance parasites via asymptomatic
carriers. The present study examined the extent of gen-
etic diversity and distribution of drug-resistant genes
among of P. falciparum in some major foci in Yemen.
A high degree of diversity of non-drug-resistant genes
(msp-2 and pfg377 and microsatellites in Chr 8) was seen
among P. falciparum in Yemen. The He index ranged
between 0.51 and 0.89, suggesting a high rate of trans-
mission and a bigger parasite population size than
anticipated in this region. Both allelic diversity and
prevalence of mixed-genotype infection were high, 57%
of the isolates harboured more than one allele at any of
the examined loci, with a mean of 1.8 genotypes per
infected individual. Assuming that each clone is readily
transmissible to mosquito, the rate of cross-mating and
subsequent recombination is expected to be high [25].
This agrees with the observed random association be-
tween loci and absence of geographical differentiation
among P. falciparum in the three sites (Dhamar,
Hodeidah and Taiz) (Fst < 0.05). Such a pattern of para-
site structure is similar to that seen among P. falciparum
populations in Africa [29,30]. These findings imply pres-
ence of a large effective population size (Ne) of P. falcip-
arum in Yemen, as there is a direct relationship between
the level of diversity and Ne [31-33]. This represents a
challenge to control efforts in the whole region, as para-
sites can readily migrate from Yemen into other sites in
the Arabian Peninsula, such as Oman [11], UAE [34]
and Saudi Arabia [35], where transmission has been
interrupted. In addition to local foci, imported malaria,
via numerous migrations from Africa/Asia, can enrich
diversity of parasites in the Arabian Peninsula. Over the
past two decades political instability has resulted in mass
movement of people from the Horn of Africa (Somalia,
Eritrea and Ethiopia) into Yemen and Saudi Arabia
[5]. Travellers from malaria-endemic areas can carry
long-lasting, transmissible, asymptomatic parasitaemia
[36,37]. Multiple introductions of distinct genetic
sources could in part explain the high level of parasite
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tween parasites in different sites suggests that the pre-
vailing epidemiological and demographical factors in
Yemen are favorable to parasite dispersal. Imported mal-
aria can, therefore, jeopardize the current success of
control in the region despite the presence of a strong
public health infrastructure. For example, countries such
as Oman experience regular epidemics due to imported
malaria [11]. To sustain malaria control and achieve
elimination in the peninsula efforts should be directed
to foci with on-going transmission, such as Yemen and
Saudi Arabia.
The distribution of drug resistant genotypes seen in
the present study fits with the history of anti-malarial
usage, and possible migration of parasites from Africa
and Asia into Yemen. The emergence of CQR in Yemen
in 1989 Yemen [2,7,9,38,39], coincided with its appear-
ance in close countries in East Africa [12,16,40] and
Asia, Saudi Arabia [3], Iran and Pakistan [3,41-46]. The
presence of two distinct pfcrt genotype, CVIET (89%)
and SVMNT (4%) suggests that CQR in Yemen has
evolved from at least two different origins. Globally,
there are five genotypes of pfcrt CVIET, SVMNT,
SVIET, CVMNT and CVTNT [47]. The CVIET geno-
type is predominant in Africa [48], while the SVMNT is
common in Asian countries close to the Arabian Penin-
sula, such as Iran [43], India [49] and Pakistan [41,42].
This agrees with the hypothesis of frequent gene flow of
African/Asian parasites into Yemen, and suggests that
the CQR genotype (CVIET) is probably introduced via
Africa, while genotype SVMNT has come from Asia.
Analysis of microsatellites around pfcrt will allow further
investigation to the origin of pfcrt resistance genotypes
[29,48].
Similar to pfcrt, high prevalence of pfmdr1 mutations was
seen in Yemen. Mutations in codon 86Y has been linked to
CQR, while those at codons 184, 1034, 1042 and 1246
are related to mefloquine (MQ), amodiaquine (AQ),
halofantrine (HF) and quinine resistance [32,50,51]. In
the present study, 86 (80%), 107 (99%) and 108 (100%)
of the examined P. falciparum isolates carried alleles
86N and 184F and 1246D, respectively. Selection of
pfmdr1 86N and 184F in recrudescent P. falciparum
parasites following lumefantrine suggested a possible
role of these alleles in the development of tolerance/re-
sistance to lumefantrine [37,52]. Increased prevalence
of pfmdr1 86N, 184F and 1246D haplotype was seen in
Zanzibar after several years of extensive use of
artesunate-amodiaquine (ASAQ) [53]. A recent study
has confirmed that P. falciparum parasites with the
pfmdr1 N86/184F/D1246 haplotype can withstand 15-
fold higher lumefantrine blood concentrations com-
pared to those with the 86Y/Y184/1246Y haplotype
[54]. The relatively high prevalence of the wild-typeallele 86 N (80%) in the present study cannot be
explained by withdrawal of CQ in Yemen, as the drug
is still in use [55], and pfcrt76T remains at a prevalence
of 89%. It is therefore, more likely that the pattern of
pfmdr1 polymorphisms, seen in Yemen, is due to
resurgence in use of artesunate-SP combination. In
addition to codon 86 and 184, mutations at the codons
1034 and 1042 were also high in Yemen; nonetheless
no mutation was seen at codon 1246. Further longitu-
dinal surveillance of pfmdr1 mutations, coupled with
in vivo testing, should be considered to examine the impact
of these polymorphisms on efficacy of ACT in Yemen.
With regard to genes controlling P. falciparum re-
sponse to SP, a previous study has detected the mutant
allele dhfr-59R among 4 out of 99 isolates in Lahj gover-
norate, southeast of Yemen, and no information was
given on other codons 51, 108 and 164 [10]. However,
the present study revealed high prevalence of mutations
at codons 51 and 108 of the dhfr, while no mutation was
seen at codon 59. This inconsistency can be attributed
to the probability that some of the samples examined by
Mubjer et al. [10] may have been collected from expatri-
ates. If mutation 59R exists among local parasites in
Yemen, it would have increase in frequency following re-
cent shift to us of artesunate + sulphadoxine-pyrimeth-
amine (SP) as first line therapy [55]. Epidemiological
evidence suggests that dhfr mutations starts at codon
108, yielding low level resistance to pyrimethamine [38],
then the resistance increases with acquisition of extra
mutations at codons 51 or 59 and 164 [56]. Analysis of
evolution pattern of dhfr genotypes shows that the high
resistance genotype (51I, 59R, 108N) accumulates mu-
tations in sequence. The most common orders of muta-
tion are 108N, 59R, 51I or 108N, 51I, 59R [57]. These
cumulative mutations in dhfr restore the parasite fitness
and allow it to overcome the effect of the drug [58]. dhfr
mutations appear earlier than dhps mutations in the de-
velopment of resistance to SP combined effect [59], and
P. falciparum has to gain mutations in dhfr and dhps
genes to develop resistance to SP, thus absence of dhps
mutation in Yemen suggest that the SP will be effective
for some years to come. Nonetheless, the occurrence of
high level resistance dhfr and dhps genotypes linked to
SP failure in areas close to Yemen, such as Iran and
Pakistan (100%), the Horn of Africa; Sudan (72.7%) and
Ethiopia (84.5%) [60-64], necessitate the need for regular
surveys to monitor possible emergence of these muta-
tions into Yemen for timely change in drug policy.
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Additional file 1: Alleles of 3 microsatellites (MS) on chromosomes
8, msp-2 and pfg377 genes among 108 Plasmodium falciparum
isolates in Yemen.
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